Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Delayed Quote. Delayed  - 05/26 04:14:37 pm
113.03 USD   -0.28%
05/25 JOHNSON & JOHNS : to Participate in the Goldman Sachs 37th Annual Gl..
05/25 AGS : Pelvic mesh implants caused dire complications
05/25DJJOHNSON & JOHNS : Washington, California Sue Johnson & Johnson Over ..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Johnson & Johnson : FDA Grants Priority Review to J&J's Bedaquiline Tuberculosis Treatment

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/31/2012 | 04:02pm CEST
   By Nathalie Tadena 
 

The Food and Drug Administration has granted accelerated approval for Johnson & Johnson's (JNJ) drug to treat a drug-resistant form of tuberculosis.

The drug, bedaquiline, has faced concerns about an imbalance of deaths seen in clinical studies. J&J's Janssen Research & Development had asked the FDA for accelerated approval of bedaquiline, which is a type of temporary approval based on less clinical data than required for traditional drug approvals.

The accelerated approval was based on data from a pair of Phase 2 studies--one of which showed 77.6% of patients in the treatment group reaching treatment success after 24 weeks compared with 57.6% of those in the placebo group--but the prescribing information for the treatment will include boxed warnings regarding increased risk of death.

Last month, an FDA panel supported a type of early approval for J&J's experimental drug; however, panel members were divided on whether bedaquiline played a role in deaths seen in clinical studies. While the FDA has said the safety data currently available for bedaquiline suggest the product appears safe, there is a potential for the highest dose of the product to cause a small change in the heart's rhythm. The FDA had said there wasn't enough data to rule out potential drug side effects on the liver and the heart. There were more deaths seen among patients being treated with bedaquiline although most of the deaths were attributed to the underlying disease.

The consumer group Public Citizen has strongly opposed the accelerated approval of bedaquiline because clinical trials showed the drug could be highly dangerous.

Only about 100 cases of drug-resistant TB are seen each year in the U.S. but the problem is more severe in typically poor countries outside the U.S.

Tuberculosis is a bacterial infection that mostly involves the lungs. It is treated with a combination of four drugs for at least six months, according to the National Heart, Lung and Blood Institute. Bedaquiline is designed to work in a new way to treat TB and would be used with other drugs.

However, there is evidence that some forms of TB can't be treated with currently available drugs, which the FDA has said "threatens to erode the progress made in the worldwide control of tuberculosis."

Tuberculosis can be fatal if it's not properly treated.

Write to Nathalie Tadena at nathalie.tadena@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on JOHNSON & JOHNSON
05/25 JOHNSON & JOHNSON : to Participate in the Goldman Sachs 37th Annual Global Healt..
05/25 AGS : Pelvic mesh implants caused dire complications
05/25DJJOHNSON & JOHNSON : Washington, California Sue Johnson & Johnson Over Vaginal Me..
05/24 JOHNSON & JOHNSON : Healthcare Sector Stock Business Review
05/24 JOHNSON & JOHNSON : U.S. FDA Expands Indication of INVOKAMET® (canagliflozin/met..
05/24 JOHNSON & JOHNSON : Washington, California sue over pelvic mesh implants
05/24 JOHNSON & JOHNSON : New Phase 3 Study Findings Show STELARA® Maintained Clinical..
05/23DJSAMSUNG ELECTRONICS : Targets U.S. Drug Market With Remicade Knockoff
05/23 JOHNSON & JOHNSON : Boomer Esiason Foundation Announces Collaboration with Johns..
05/23 JOHNSON & JOHNSON : Janssen's Single-Agent DARZALEX® (daratumumab) Approved by E..
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials